A Los Angeles biotech is joining the ranks of startups looking to make use of the powerhouse of the cell, with RA Capital and Insight Partners co-leading a $35 million funding round for Capacity Bio.
Based on work done by UCLA professor Orian Shirihai and University of Arizona professor Kathleen Rodgers, the biotech is working on new targets that affect the mitochondria, CEO Ken Horne told
Endpoints News
. The funding will take the lean startup into 2025 through various clinical milestones, added the CEO, who previously led venture creation for Capacity’s incubator, Remiges Ventures.
Unlock this story instantly and join 164,100+ biopharma pros reading Endpoints daily — and it's free.